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2Abstract17
In addition to clinical signs of infection (e.g. inflammation, purulence and pain), a microbial18
ĐŽƵŶƚŽĨA? ? ? ?ĐŽůŽŶǇ ?ĨŽƌŵŝŶŐƵŶŝƚƐ ?ŐŚĂƐŚŝƐƚŽƌŝĐĂůůǇďĞĞŶƵƐĞĚƚŽĚĞĨŝŶĞǁŽƵŶĚŝŶĨĞĐƚŝŽŶ ?19
However, it is increasingly recognised that, rather than a high bioburden level alone being20
detrimental to wound healing, it is the virulence of the invading microorganism and the host's21
immune status that can affect clinical outcomes. Bacteria, such as Pseudomonas aeruginosa,22
Staphylococcus aureus and Staphylococcus epidermidis, have developed a range of virulence23
factors to help themovercome host defences and proliferatewithin the underlying soft tissue.24
More specifically, bacterial proteases are one such virulence factor that has been implicated25
in promoting the invasion and destruction of the host tissue. Because of the complexities of26
microorganisms, the proteases can negatively impact the wound environment, leading to27
delayed wound healing. The aim of the present paper is to describe various extracellular28
bacterial proteases; review the impact they have on the wound environment, the host29
immune response and biofilms; and discuss potential wound management strategies against30
them. The evidence discussed suggests that proteases may play a profound role in wound31
infections, contribute to the development of an inflammatory response and impede wound32
healing.33
34
3Introduction35
The wound-healing process consists of four highly integrated and overlapping phases:36
haemostasis, inflammation, proliferation and tissue remodelling [1]. Multiple factors can lead37
to impaired wound healing. Some are systemic factors, whereby the overall health or disease38
state of the individual affects his or her ability to heal [2]. Examples of systemic factors known39
to impact wound healing are patient age, ischaemia and pre-existing medical conditions such40
as diabetes [2]. Local factors that directly influence the characteristics of the wound itself may41
also contribute to delayed healing. Local factors include oxygenation, venous insufficiency42
and infection [2]. When skin is injured, it allows microorganisms to access the underlying43
tissues, leading to wound infection.Wound infection has various stages of increasing severity,44
from contamination to colonisation, local infection/critical colonisation and/or spreading45
invasive infection [2]. This is known as the continuum of infection [3].46
47
Many of the causative organisms of wound infections are opportunistic pathogens; these48
microorganisms may be part of the body's normal flora (e.g. Staphylococcus spp.,49
Streptococcus pyogenes) or be commonly found in the environment (e.g. Pseudomonas50
aeruginosa). These organisms can exploit an ecological advantage, such as an51
immunocompromised host or a breech in the skin, to cause disease. The ability of such52
bacteria to cause disease is influenced by a variety of factors, including the number of bacteria53
present (known as the bioburden), the site of infection and the virulence factors of the54
microorganism. Virulence factors are produced by microorganisms and contribute to their55
pathogenicity [4-6].56
57
Occasionally, the physical presence of bacteria may cause disease in the host; for example,58
high levels of bacteria may obstruct heart valves in endocarditis [7]. More commonly,59
however, virulence factors, such as enzymes or toxins produced by the microorganism, are60
the primary cause of detriment to the host [4, 6]. Examples of virulence factors contributing61
to disease can be found in conditions such as toxic shock syndrome [8] and Clostridium62
difficile-associated diarrhoea, where the symptoms of pseudomembranous colitis are caused63
by the effects of bacterial exotoxins [9, 10]. The same trend can be observed in sequelae such64
as wound infections [4].65
66
Historically, a swab or biopsy sample returning a microbial count of >105/g tissue has been67
associated with wound infection and delayed wound healing [11, 12]. For some bacteria, such68
as S. pyogenes  ?ɴ ?ŚĂĞŵŽůǇƚŝĐ ^ƚƌĞƉƚŽĐŽĐĐŝ ? 'ƌŽƵƉ  ^ƚƌĞƉƚŽĐŽĐĐŝ ? ? ůĞǀĞůƐ ĨĂƌ ďĞůŽǁ AM ? ? ? ?Ő69
tissue have been reported as leading to infection [13, 14]. Conversely, some wounds70
containing less pathogenic organisms, such as enterococci or diphtheroids, have been71
reported to heal with bioburden levels above 105/g tissue [4, 15]. Whilst the quantity of72
pathogenic bacteria in a wound has been shown to influence healing, this quantitative73
threshold and healing rate is also affected by endogenous host factors, such as the status of74
the immune system, underlying aetiologies and comorbidities, compounded by the type of75
4microbial species present and their associated virulence factors [15, 16]. The complexity of76
ƚŚĞ ĞƐƚĂďůŝƐŚŵĞŶƚ ŽĨ ŝŶĨĞĐƚŝŽŶ ĐĂŶ ďĞ ĞǆƉƌĞƐƐĞĚ ĂƐ ? /ŶĨĞĐƚŝŽŶരA?രŵŝĐƌŽďŝĂů ďŝŽďƵƌĚĞŶ ǆ77
virulence/host resistance [17].78
79
Overview of bacterial virulence factors80
Virulence factors are molecules produced by microorganisms that contribute to the81
pathogenicity of the organism. There are many types of virulence factors, including adhesins,82
capsules, endotoxins, exotoxins, flagella, lipases, pilli and proteases. They can have a myriad83
of functional roles, including the capacity to facilitate microbial attachment, invasion or both84
as well as the promotion of the growth of a microbe in a host through avoidance of host85
detection, inhibition of phagocytosis and regulation of the capacity for intracellular survival86
[18]. Of these, proteases are discussed further in the following sections.87
88
Bacterial proteases89
Proteases are produced by a variety of microorganisms including both Gram-negative and90
Gram-positive bacteria, fungi and viruses [19-22]. Many pathogenic bacteria produce a range91
of proteases [23, 24], of which a number of the bacteria characterised as producing proteases92
are known wound pathogens and include Staphyloccocus spp., Streptococcus spp.,93
Enterococcus spp. and P. aeruginosa [19, 20]. Table 1 lists common organisms and the94
proteases they produce. It is important to note, however, that despite the importance of95
bacterial proteases in delayed healing, the majority of proteases in non-healing wounds are96
endogenous; that is, they are produced by the host themselves as a result of prolonged97
inflammation [25].98
99
Proteases can be broadly classified according to the location at which they cleave the target100
protein. Exoproteases cleave at or near the carboxi or amino terminals, whereas101
endopeptidases can cleave at up to five residues from these terminals [26]. This broad102
classification is not inclusive of all proteases as some, such as ADP-dependent proteases, do103
not fit this definition [27]. Proteases can be further categorised according to their catalytic104
activity and include aspartic proteases, cysteine proteases, glutamic proteases,105
metalloproteases, serine proteases and threonine proteases [28, 29].106
107
Bacterial proteases can act either extracellularly or intracellularly. Processes such as108
sporulation and protein maturation within the microbial cell involve/require intracellular109
proteases [25], whilst extracellular protease are active outside of the microbial cell where110
they interact with the host environment to aid in the survival and proliferation of the111
microbial cell. The physiological function of extracellular bacterial proteases is to provide112
peptidic nutrients for the bacteria by hydrolysing (degrading) proteins in their surrounding113
environment [20, 28]. However, a fortuitous by-product of protease production for the114
microorganism is the degradation of host proteins, growth factors and receptors, which can115
impede the immune response and contribute towards tissue degradation, enabling further116
microbial dissemination into the underlying soft tissue [19, 23, 30-33]. Arguably, microbial117
proteases are considered to be among the most important type of microbial virulence factor118
influencing wound healing [20, 34, 35].119
5Impact of wound environment on production of bacterial proteases120
As with other virulence factors, production and release of bacterial proteases may be121
mediated by regulatory factors, which govern the transcription of protease genes in response122
to the local environment of the bacteria [36]. Production may be influenced by a variety of123
factors, including nutrient availability, quorum sensing (a cell density-dependent signalling124
mechanism), growth phase, osmolarity, pH and temperature [37-43]. Such factors may be125
encountered during infection of the soft tissue [36].126
127
Research conducted in vitro on protease production by 95 clinical strains of Enterococcus128
faecalis, specifically looking at Gelatinase (GelE), indicated that production of this protease is129
influenced by carbon source availability, pH, presence of divalent cations and temperature,130
suggesting that such conditions could affect the virulence of E. faecalis clinically [43]. A131
notable observation from this study was the effect of pH on GelE production, whereby132
ƉƌŽƚĞĂƐĞĂĐƚŝǀŝƚǇƉĞĂŬĞĚĂƚĂƌŽƵŶĚƉ,ര ?ďƵƚĚĞĐƌĞĂƐĞĚĂƐƚŚĞƉ,ŽĨƚŚĞĐƵůƚƵƌĞŵĞĚŝƵŵǁĂƐ133
lowered [43]. Additionally, it was also observed that the addition of iron, copper or zinc to the134
culture media either completely eliminated, or dramatically reduced, GelE activity [43].135
Interestingly, iron availability has also been shown to affect protease production in other136
bacteria, with P. aeruginosa protease IV expression found to be enhanced upon iron limitation137
[42].138
139
Impact of bacterial proteases on the wound environment140
The impact of bacterial proteases has been documented in a range of acute and chronic141
medical conditions, including impairment of lungs in the cystic fibrosis patient [44], eye142
infections [45-47], gastroenteritis [48] and wound infections [19, 21]. Themajority of bacterial143
proteases research has focussed on the Gram-negative bacterium P. aeruginosa, where a144
strong correlation between the severity of an infection and P. aeruginosa protease levels has145
been reported, with higher levels of the P. aeruginosa elastase linked to increased146
inflammation and tissue damage [49, 50],whilst protease-deficient P. aeruginosa strains have147
been found to be less virulent than their protease-producing counterparts in burn wound148
mouse models [51, 52].149
150
P. aeruginosa produces a number of proteases, with 155 of 5568 predicted genes of the151
commonly studied type strain PAO1 strain estimated to encode proteases [53, 54]. Elastase B152
(pseudolysin; LasB), a major metalloproteinase expressed by P. aeruginosa, has been153
demonstrated to degrade collagen and is thought to play a key role in cystic fibrosis lung154
infections [55]. This role is supported by several studies that have detected P. aeruginosa155
proteases in the lungs of cystic fibrosis patients [56-58]. Such collagen-degrading activity of156
P. aeruginosamay also occur in wound infections and may contribute to tissue damage [59].157
158
Impact of bacterial proteases on the host immune response159
If the protective barrier of the epidermis is breached due to a cut, abrasion or bite for160
example, it allows bacteria access to the underlying tissue where they may colonise, migrate161
and proliferate, leading to localised infection. During these initial phases, it is of benefit to the162
organisms to impede the immune response and so ensure the best possibility of its survival.163
Bacterial proteases play a significant role in the inhibition of the hosts' immune response164
through a range of mechanisms including induction of an inflammatory reaction, reduction in165
6phagocytosis, inactivation of the complement system, cytokine degradation, immunoglobulin166
degradation and inactivation of antimicrobial peptides (AMPs).167
168
Induction of inflammatory reaction169
Wound healing is a complex series of overlapping phases (inflammation, proliferation and170
tissue remodelling) that involves amyriad cells andmediators [60]. An inflammatory response171
is a typical and necessary part of normal wound healing and occurs as blood vessels dilate,172
which allows antibodies, white blood cells, enzymes and other beneficial elements into the173
affected area [61]. In some instances, bacterial proteases can also induce a host inflammatory174
response. For example, P. aeruginosa elastase A (LasA) protease enhances activity of several175
host elastolytic proteases, including human leukocyte elastase and human neutrophil elastase176
[62]. Whilst this may appear counterintuitive for the survival of the organism as it aids the177
removal of bacterial organisms from the site, if this inflammatory phase is prolonged, this can178
result in a prolonged elevation of the host's immune response, including host proteases,179
leading to wound chronicity [19, 63]. In these cases, the host's own immune components180
actively degrade the surrounding tissue without resolving the infection, facilitating the further181
dissemination of the infection into the surrounding and deeper-seated tissues.182
183
One of the most notorious examples of a host immune component providing a dual role in184
wound healing are the matrix metalloproteinases (MMPs), which function in the extracellular185
environment of cells and degrade both matrix and non-matrix proteins. They play central186
roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury,187
with several studies indicating that bacterial proteases may up-regulate host MMP188
production [64, 65]. MMPs play an important role in wound healing, facilitating several189
important processes including angiogenesis; removal of damaged extracellular matrix (ECM);190
transition of epithelial cells, fibroblasts and vascular endothelial cells across the ECM;191
contraction of scar ECM; and scar remodelling [66-71]. However, some chronic wounds192
become stalled in the inflammatory phase of wound healing. In these instances, components193
pivotal in wound healing, such as growth factors, are degraded, and host proteases are194
abnormally elevated [72]. A direct consequence of abnormally elevatedMMP activity includes195
a reduction in wound closure rates [73-75].196
197
A further example of bacterial proteases contributing to induction of an inflammatory198
reaction in the host is through the proteases of S. pyogenes and Staphylococcus aureus.199
Proteases produced by these bacteria have been found to activate the kinin system and200
degrade kininogens, which subsequently induce an inflammatory reaction of oedema,201
redness and pain [34]. In addition, release of bacteria into the circulation may be promoted202
by kinin-enhanced vascular leakage, which will potentially allow for the spread of infection203
and may further perpetuate the pathophysiology of infectious diseases [34].204
Reduction in phagocytosis205
206
Similar to other immunological factors, phagocytosis can also be hindered by bacterial207
proteases [76]. The P. aeruginosa proteases alkaline protease (aeruginolysin; AprA) and LasB208
have been found to reduce leucocyte activity [77], inhibit the function of neutrophils and209
interfere with their chemotaxis [78]. The S. aureus cysteine protease staphopain B (SspB) can210
inhibit neutrophil phagocytosis and can also reduce neutrophil chemotactic activity [79, 80].211
The intracellular survival of S. pyogenes in macrophages has been shown to be enhanced by212
7the streptopain (SpeB) cysteine protease in vivo [81], while Chiang-Hi and colleagues reported213
that SpeB can also prevent immune clearance of S. pyogenes by causing mitochondrial214
damage in polymorphonuclear neutrophils (PMN) [82].215
Inactivation of the complement system216
217
Complement involves a group of proteins that provide enzymatic activity and produce218
effector molecules, facilitating a range of immunological functions such as cell lysis (C5b-9),219
inflammation (C3a, C5a) and phagocytosis (C3b) [83]. Proteins C3 and C5 are involved in the220
initiation of an immune response and, as such, present as targets for bacterial proteases [84].221
P. aeruginosa protease IV (lysyl endopeptidase; iron-regulated protein PrpL) can degrade a222
range of biologically important host proteins, such as the complement components C3 and223
C1q [85], whereas the S. pyogenes protease SpeB can prevent formation of C5 by degrading224
C3 [86, 87]. Consequently, as coating of bacteria with C3 is prevented, opsonisation and225
neutrophil phagocytosis is hindered or even prevented [84]. A further role of SpeB with226
respect to disarming the complement system is to cleave properdin. Properdin stabilises the227
formation of the C5 [88]. As such, cleavage of properdin can make the bacteria less228
susceptible to opsonophagocytosis by neutrophils [84]. Other bacterial species, such as the229
Gram-positive enteric bacterium E. faecalis, are also capable of inactivating complement. The230
protease gelatinase (coccolysin; GelE) of this microorganism is able to inactivate the host231
complement system by degrading C3 [89].232
Cytokine degradation233
234
ǇƚŽŬŝŶĞƐĂƌĞƐŵĂůůƉƌŽƚĞŝŶƐ ? ? ? ? ?രŬĂ ?ƚŚĂƚŝŶĐůƵĚĞĐŚĞŵŽŬŝŶĞƐ ?ĐŽůŽŶǇ ?ƐƚŝŵƵůĂƚŝŶŐĨĂĐƚŽƌƐ235
(CSF), interferons (IFN), interleukins (IL) and tumour necrosis factors (TNF) and are released236
in response to tissue damage. The many functions performed by cytokines include activation237
of phagocytic cells, antiviral and anti-parasitic activity, chemotaxis of neutrophils and T-cells,238
growth of macrophage colonies and proliferation of B- and T-cells. As such, cytokines239
represent an ideal target for bacteria in overcoming the host immune system, and a range of240
bacterial proteases have been found to be able to degrade cytokines and their receptors [84].241
P. aeruginosa proteases hinder a range of cytokine activities and are also able to induce242
degradation of cytokines [59]. Examples include AprA degradation and inactivation of human243
ŝŶƚĞƌĨĞƌŽŶɶ ?/E& ?ɶ ? ? ? ? ? ?ĂŶĚŝŶĂĐƚŝǀĂƚŝŽŶŽĨŚƵŵĂŶ ƚƵ ŽƵƌŶĞĐƌŽƐŝƐĨĂĐƚŽƌ ?ɲ ?dE& ?ɲ ?ďǇ>ĂƐ244
 ? ? ? ? ? ? ? ?ŽƚŚ/E& ?ɶĂŶĚdE& ?ɲƉůĂǇĂŶŝŵƉŽƌƚĂŶƚƌŽůĞŝŶ ŚĞŚŽƐƚŝŵŵƵŶĞƌĞƐƉŽŶƐĞ ?ǁŝƚŚĂ245
ůĂĐŬŽĨ/E& ?ɶƌĞƐƵůƚŝŶŐŝŶĂƵƚŽ ?ŝŶĨůĂŵŵĂƚŽƌǇĚŝƐĞĂƐĞ  ? ? ? ? ? ? ?ĂŶĚdE& ?ɲŝŶǀŽůǀĞĚŝŶƐǇƐƚĞŵŝĐ246
inflammation and apoptosis [77]. The P. aeruginosa large extracellular protease (LepA) also247
increases IL-8 production and secretion [50, 94], which may have a detrimental effect on the248
host by elevating and prolonging an inflammatory response [95]. Another putative serine249
protease of P. aeruginosa (PA0328, also designated AaaA) has been shown to provide the250
bacterium with a selective advantage at establishing infection and long-term survival in a251
ĐŚƌŽŶŝĐŵŽƵƐĞǁŽƵŶĚŵŽĚĞů ?dŚĞĂƵƚŚŽƌƐĂůƐŽŶŽƚĞĚƚŚĂƚŚŝŐŚĞƌůĞǀĞůƐŽĨdE& ?ɲĂŶĚ/> ? ?ɲ252
expression was detected in response to the wild-type P. aeruginosa strain compared with an253
AaaA deletion mutant [96]. Bacterial proteases from other organisms such as L. monocytes,254
Serratia marcescens and S. aureus have also been shown to elevate interleukin levels [22].255
256
Proteases of the Gram-positive skin pathogen S. pyogenes can also affect cytokine activity.257
The S. pyogenes protease SpeB can cleave the IL-1 precursor to produce biologically active IL-258
1, a principle mediator of inflammation [97]. An additional protease of S. pyogenes,259
8Streptococcal chemokine protease (ScpC), has been found to degrade IL-8 [34]. Given that IL-260
8 mediates neutrophil migration and activation, expression of ScpC can be detrimental to the261
host immune response. Proteases produced by other bacteria  for example, the Gram-262
positive skin pathogen S. aureus  can also interfere with IL-8 function. The serine proteases263
of this bacterium can modulate IL-8 synthesis [98].264
Degradation of immunoglobulins265
266
A further function of bacterial proteases in overcoming the host immune system is in the267
degradation of host immunoglobulin [59]. This can be particularly detrimental to the host268
given the role of immunoglobulins in recognising and contributing to the neutralisation of269
invading microorganisms. Various groups have reported the impact of P. aeruginosa270
proteases on the degradation of immunoglobulins and include the degradation of271
immunoglobulin A (IgA) and immunoglobulin G (IgG) by P. aeruginosa protease LasB and272
protease IV [47], respectively [99]. The Proteus mirabilismetalloprotease ZapA has also been273
implicated in degrading IgA [100, 101].274
275
Inactivation of antimicrobial peptides276
AMPs are antimicrobial agents produced by eukaryotic organisms to prevent microbial277
invasion. In humans, specific roles of antimicrobial peptides include killing invading bacteria278
primarily by disrupting the membrane integrity of the bacterial cell wall [84]. In general, AMPs279
are relatively resistant to proteolytic degradation, although there are some bacteria that are280
capable of producing proteases effective at cleaving and inactivating AMPs [84].281
282
The strict anaerobe and opportunistic bacterium Finegoldia magna associated with skin283
infections produces a subtilisin-like serine protease SufA, which targets the human284
cathelicidin AMP LL-37 [102]. AMP LL-37 is also targeted by other bacterial proteases285
including SpeB of S. pyogenes, elastases of P. aeruginosa, GelE of E. faecalis and ZapA of P.286
mirabilis [102]. Proteolytic degradation of AMP LL-37 prevents binding of this antimicrobial287
peptide to the invading bacteria and, as such, destroys the bactericidal activity of the peptide288
[84]. Interestingly, recent data indicate that inactivation of LL-37 by the S. pyogenes protease289
SpeB can be found in patients with severe S. pyogenes soft tissue infections [103].290
Bacterial proteases contributing to invasion291
292
Once the innate barrier of the skin has been compromised and bacteria have gained entry to293
the underlying soft tissue, bacterial proteases can help the microorganism spread from the294
initial site of infection and invade the surrounding tissue [19, 20, 77, 104]. The presence of295
bacterial proteases and additional disruption of the epithelial barrier by these enzymes296
further compromises the protective barrier of the skin, which may allow other microbial297
species access to the location [34]. Specific examples of potential wound pathogens using298
proteases to contribute to invasion are discussed below.299
300
Pseudomonas aeruginosa301
P. aeruginosa proteases, including AprA, LasA, LasB and protease IV, can cause tissue damage302
during P. aeruginosa infections [59]. These proteases cause the proteolytic inactivation of the303
pathogen's adhesive molecules, which aids in the dissemination of bacteria from the initial304
site of infection [34]. Components of connective tissue, including collagen and elastin, have305
been demonstrated as being degraded by P. aeruginosa proteases in vitro [105, 106]. This306
9may have a detrimental effect on wound healing because collagen controls cellular functions307
(e.g. cell differentiation and cell migration) that are important during the phases of wound308
healing [107]. P. aeruginosa elastase B and alkaline proteases have also been found to309
ĚĞŐƌĂĚĞ ůĂŵŝŶŝŶɲ ?>' ? ? ? ?ĂĐŽŵƉŽŶĞŶƚŽĨƚŚĞďĂƐĞŵĞŶƚŵĞŵďƌĂŶĞ ŝŶŚƵŵĂŶƐŬŝŶ  ? ? ? ? ? ?310
Additionally, P. aeruginosa proteases may have a role in invasion and haemorrhagic tissue311
necrosis in infections [77], whilst protease IV can degrade fibrinogen [109].312
313
LasA and LasB are among the most researched P. aeruginosa proteases and are thought to314
play a role in the pathogenesis of some P. aeruginosa strains [77, 110-113]. P. aeruginosa315
elastases have been found in clinical wound fluid samples [59] and are capable of degrading316
proteins on the surface of fibroblasts and inhibiting fibroblast growth [34]. Moreover, the P.317
aeruginosa protease LasA is involved in host ectodomain shedding whereby cell surface318
proteins are cleaved [114, 115], leading to epithelial disruption, tissue penetration and319
endothelial damage [116, 117]. P. aeruginosa strains producing LasB have also been found to320
inhibit fibroblast growth and degrade proteins from human wound fluid and skin biopsies [21,321
59]. These observations suggest that P. aeruginosa proteases may be detrimental to wound322
healing [59].323
324
Quorum sensing has been shown to contribute to the virulence of P. aeruginosa. For example,325
quorum sensing can regulate the expression of various virulence factors in P. aeruginosa,326
including pyocyanin, rhamnolipids and proteases such as the elastases LasA and LasB [77,327
118]. The role of quorum sensing in infection has been demonstrated using quorum sensing-328
deficient P. aeruginosa strains in a range of in vivo models designed to mimic various329
conditions, including acute and chronic lung infections, burn wound infection and microbial330
keratitis. In these studies, the inability of quorum sensing-deficient strains to induce infection331
was thought to be due to decreased production of proteases and rhamnolipid [119-122].332
These observations would appear to suggest that protease production in wound infections333
with P. aeruginosa increases as the density of the P. aeruginosa reaches a critical threshold.334
335
Staphylococcus aureus336
S. aureus proteases, such as Ssp (V8, a serine protease), can mediate a phenotypic change in337
the bacterium from adhesive to invasive by degrading its surface-associated adhesins [34].338
The proteolysis of fibronectin-binding proteins by V8 decreases the adhesive phenotype of S.339
aureus, allowing for the diffusion of the pathogen. Such proteases (e.g. staphopain A) can also340
degrade host tissue, including collagen and elastin [34]. For example, the Staphopain A (ScpA)341
protease of S. aureus has comparable elastinolytic activity to host neutrophil elastase. This342
may contribute to the degradation of connective tissue in staphylococcal infections [123].343
Additionally, similar to P. aeruginosa proteases, metalloprotease aureolysin and the serine344
proteinase V8 of S. aureusĐĂŶĂůƐŽĐůĞĂǀĞůĂŵŝŶŝŶɲ ?>' ? ? ? ? ? ? ? ? ?345
346
Staphylococcus epidermidis347
Staphylococcus epidermidis, a Gram-positive bacterium associated with the normal flora of348
healthy skin, may be pathogenic in immunocompromised patients and has been found to be349
responsible for surgical wound infections. Research indicates that the S. epidermidis cysteine350
protease (Ecp) has a similar sequence to ScpA and SspB proteases of S. aureus [124].351
Moreover, Ecp mode of action is similar to ScpA and SspB in that it has elastinolytic activity.352
10
Consequently, this may contribute to the invasiveness and pathogenicity of S. epidermidis in353
wounds [124].354
355
Streptococcus pyogenes356
Proteases play a pivotal role in the invasiveness of S. pyogenes, as indicated by S. pyogenes357
protease deletionmutants that were found to be two- to threefold less invasive than the wild-358
type strains when assessed in vitro on epithelial cells [125]. Additionally, numerous authors359
report that SpeB (streptopain) may affect the severity andmigration of S. pyogenes infections360
[126-131]. SpeB has also been shown to be produced in vivo during infection in mouse and361
primate models [132-134] and can degrade fibronectin (1993) [135]. Other S. pyogenes362
proteases include Streptolysin S, which is involved in skin penetration [34], and IdeS363
(immunoglobulin G-degrading enzyme), which inhibits opsonophagocytosis [136].364
365
Finegoldia magna366
Finegoldia magna is a Gram-positive anaerobic bacterium associated with the normal367
microbiota of the skin. In immunocompromised hosts or when the normal microflora of the368
skin is disrupted, however, F. magna may act as an opportunistic pathogen [137]. In such369
circumstances, F. magna has been commonly isolated from chronic wounds including diabetic370
and pressure ulcers [138-143].371
372
Contributing to tissue invasion by F. magna is the serine protease SufA [102, 137, 144]. Using373
F. magna SufA deletion mutants and electron microscopy, Murphy and colleagues eloquently374
demonstrated that SufA can degrade collagen IV and collagen V, potentially enabling this375
opportunistic pathogen to establish a deep-seated infection [137].376
377
A further example of the influence of environmental conditions on the production of378
proteases can be found with S. pyogenes [36, 145]. Using a mouse soft tissue model,379
Loughman and Caparon identified a number of environmental factors, including growth380
phase, pH and NaCl concentration, which altered the activity of the SpeB protease [36].381
Consistent with other publications, the authors also found that SpeB protease activity was382
associated with low pH [109, 146, 147]. The authors noted that as S. pyogenes entered383
ƐƚĂƚŝŽŶĂƌǇƉŚĂƐĞ ?ƚŚĞĐƵůƚƵƌĞŵĞĚŝƵŵĨĞůů ĨƌŽŵĂŶ ŝŶŝƚŝĂůƉ,ര ? ? ?ƚŽƉ,ര ? ?ǁŝƚŚ^ƉĞĂĐƚŝǀŝƚǇ384
peaking in stationary phase. When a culture medium was buffered to maintain a constant pH385
ŽĨ ĂƌŽƵŶĚ Ɖ,ര ? ? ^ƉĞ ĂĐƚŝǀŝƚǇ ǁĂƐ ŝŶĚĞƉĞŶĚĞŶƚ ŽĨ ŐƌŽǁƚŚ ƉŚĂƐĞ ? ŵĞĂŶŝŶŐ ƚŚĂƚ ƉƌŽƚĞĂƐĞ386
activity could be induced in exponential phase. NaCl concentration was also shown to affect387
the activity of SpeB, with limited protease expression detected at physiological levels of NaCl388
 ? ? ? ?രŵD ?ĂŶĚŝŶĐƌĞĂƐŝŶŐƉƌŽƚĞĂƐĞĂĐƚŝǀŝƚǇĚĞƚĞĐƚĞĚĂƐƚŚĞEĂůĐŽŶĐĞŶƚƌĂƚŝŽŶǁĂƐŝŶĐƌĞĂƐĞĚ389
[36]. Such conditions may be encountered in a clinical setting, and variations in the wound390
environment could impact bacterial protease production.391
Protease activity in biofilms392
393
It is increasingly acknowledged that many microorganisms have a predisposition to attach to394
surfaces, aggregate and form biofilms [148]. Biofilms are complex microbial communities395
containing bacteria and fungi. The microorganisms synthesise and secrete a protective matrix396
that attaches the biofilm firmly to a living or non-living surface [149].397
398
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Given the frequent isolation of biofilms from a wide range of environments, it is perhaps399
unsurprising that they have been detected in chronic wounds, which provide ideal conditions400
for bacterial attachment and proliferation [150]. The wound bed often contains necrotic401
tissue and debris, aiding bacterial adherence, while exudate provides nutrients to support402
bacterial growth [151, 152]. Additionally, chronic wounds are often associated with an403
impaired host immune response, increasing susceptibility to infection [151-153].404
405
A study by James et al. using microscopy techniques reported that 60% of chronic wound406
specimens contained a biofilm, compared with only 6% of acute wound samples examined407
[150]. Other research groups reported biofilms in 4759% of chronic wounds tested,408
correlating well with James' data [154, 155]. A further study suggests the figure could even409
be as high as 90% [156].410
411
Upon the transition from planktonic or free-floating bacteria to the establishment of a412
biofilm, bacteria undergo a general reduction in growth rates and metabolic activity, possibly413
contributing to a reduced susceptibility to antimicrobials [157]. Such reductions in metabolic414
activity and the establishment of the biofilm phenotype are associated with down-regulation415
of a number of genes [157]. Work by Evans et al. on S. epidermidis biofilms in vitro, however,416
suggests that protease-encoding genes are not down-regulated in this way [158]. In this study,417
total protease activity was analysed using a casein assay and showed that protease activity418
was detected in S. epidermidis biofilms at levels over and above S. epidermidis planktonic419
populations. Moreover, protease activity increased as the growth rates of the biofilm and420
planktonic populations were increased, with protease activity of the biofilm always exceeding421
that detected for planktonic cultures [158]. Another study using an in vitro and in vivo C.422
elegans infection model demonstrated that secretion of S. epidermidis proteases inhibited423
the development of S. aureus biofilms, which wasmainly due to serine protease activity [159].424
It has also been reported that S. aureus proteases (e.g. metalloprotease aureolysin and Sp1425
protease) are involved in detaching established biofilms (i.e. targeting the surface adhesions)426
[34].427
428
Novel wound management strategies429
Due to the detrimental impact of bacterial proteases on the host and the ubiquitous nature430
of these enzymes, they could be exploited for the development of a point-of-care diagnostic.431
It is now increasingly recognised that bioburden alone does not necessarily correlate with432
infection, particularly in the early stages, where clinical signs of infection may be difficult to433
define [160]. In addition, the clinical signs of infection (pain, swelling, heat, redness, exudate)434
may not be present in patients with comorbidities that suppress the immune response, such435
as diabetes [161]. Under such circumstances, a bacterial protease point-of-care diagnostic436
may help clinicians decide when bacteria present in a wound are problematic [162]. This437
would help guide clinicians as to when it would be most appropriate to administer438
prophylactic treatment.439
440
Serena and coworkers have described a novel point-of-care diagnostic test capable of441
identifying a wound in a state of pathogenesis even before the clinical signs of infection442
become apparent [163]. Using wound fluid swab samples collected from 366 chronic wounds,443
the authors noted that elevated levels of bacterial protease activity (BPA) was detected in444
49% of wound fluid samples despite only 18% of this cohort of patients demonstrating three445
12
or more signs of clinical infection. Using elevated BPA as a marker, early identification of446
wounds in a state of pathogenesis, but where infection is not obvious to the clinician, could447
lead to a rapid response to reduce bacterial bioburden [161]. Such prompt action could448
improve the clinical outcome and could have potential economic benefits [164, 165].449
Identification of elevated BPA in chronic wounds also provides a novel target for the future450
development of bacterial protease inhibitors.451
452
Conclusions453
Although the pathogenicity of a bacterium is the combined activity of the multiple virulence454
factors present in its portfolio, proteases remain a central means in enabling the455
microorganism to overcome the host defences and proliferate. Indeed, some authors even456
regard proteases as the most effective virulence factor in the establishment of infection [20,457
35, 84], with functions including overcoming the host immune system, tissue degradation and458
promoting the up-regulation of additional virulence factors. Taken together, the evidence459
discussed in the present review suggests that proteases play a central role in the460
establishment of wound infections, contribute to the development of an inflammatory461
response and can impede wound healing.462
463
464
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TABLES.1082
1083
Table 1. Proteases from common organisms [adapted from Koziel and Potempa (2012) [34]]1084
1085
Organism Bacterial protease
Pseudomonas aeruginosa Las A (elastase A)
Las B (elastase B)
AprA (alkaline protease)
Protease IV
Staphylococcus aureus Aureolysin
ScpA (staphopain A)
SspB (staphopain B)
SspA (staphylococcal serine protease)
Streptococcus pyogenes SpeB (streptopain; cysteine proteinase)
Streptlysin S
IdeS (cysteine proteinase)
ScpC
Enterococcus faecalis GelE (gelatinase)
SprE (serine protease)
Staphylococcus epidermidis Esp (serine protease)
Finegoldia magna SufA (subtilisin-like serine protease)
Proteus mirabilis ZapA (metalloprotease)
Aeromonas sobria ASP (serine protease)
Vibrio vulnificus metalloprotease
1086
1087
